Research Paper Volume 16, Issue 11 pp 9410—9436

Figure 7. APOA5 expression estimates poor prognosis and chemotherapy resistance in CRC patients. (A) The APOA5 protein was observed in the cytoplasm of CRC cells, which was analyzed with IHC staining. Bar = 50 μm. (B) The percentage of APOA5 positive expression in the specimens with wild-type PIK3CA or mutant ones. (C, D) Kaplan-Meier analysis of the disease-free survival (DFS, D) and overall survival (OS, C) between APOA5 positive and negative tumors in 378 CRC patients. P-value was obtained from two-sided log-rank tests. (E) The percentage of APOA5 expression in the patients effective and resistant to first-line chemotherapy. (F) Chemotherapy responses among patients with APOA5 positive and negative tumors. (G) The hazard ratio of APOA5 expression for chemotherapy resistance in three independent cohorts was analyzed with forest plot. The size of each square is proportional to the number of patients in each cohort. The area of the squares reflects the study-specific weight. Horizontal lines represent 95% confidence intervals (CI). Diamonds represent the pooled risk ratio and 95% CI of APOA5 expression. p-values < 0.05 are represented as a^*.